Zacks Investment Research upgraded shares of ITUS (NYSE:ANIX) from a hold rating to a buy rating in a research note released on Wednesday, Zacks.com reports. They currently have $3.50 target price on the stock.
According to Zacks, “Anixa Biosciences, Inc. operates as a bio-technology company. It develops diagnostics and therapeutics to detect cancer. Anixa Biosciences Inc., formerly known as ITUS Corporation, is based in San Jose, United States. “
Separately, B. Riley lowered their price target on ITUS from $11.25 to $8.00 and set a buy rating for the company in a report on Monday.
Shares of NYSE ANIX opened at $3.28 on Wednesday. The stock has a 50 day moving average price of $3.47 and a 200 day moving average price of $3.91. ITUS has a 52-week low of $2.78 and a 52-week high of $5.70.
ITUS Company Profile
Anixa Biosciences, Inc engages in the development, acquisition and licensing emerging technology in the field of biotechnology. It focuses on platform called Cchek, a series of inexpensive non-invasive blood tests for the early detection of cancer, which is based on the body’s immunological response to the presence of a malignancy.
Recommended Story: Stock Symbol
Get a free copy of the Zacks research report on ITUS (ANIX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com